Ultime notizie per Avalo Therapeutics (NASDAQ:AVTX) Azioni

Avalo Therapeutics

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Avalo Therapeutics Inc

Avantium NV

<p>Pennant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNTG#NASDAQ">PNTG</a>) raises FY2024 Adj EPS guidance from $0.89-0.95 to $0.90-0.96 vs $0.91 analyst estimate. Raises FY2024 sales outlook from $654.00 million-694.50 million to $665.30 million-706.50 million vs $679.26 million estimate.</p>


News

Guidance

PNTG

Pennant Gr Raises FY2024 Adj EPS Guidance from $0.89-0.95 to $0.90-0.96 vs $0.91 Est; Raises FY2024 Sales Guidance from $654.00M-694.50M to $665.30M-706.50M vs $679.26M Est

CHRD

Chord Energy Expects FY24 Adj. EBITDA $2.7B, Adj. Free Cash Flow On Pro Forma Basis Of $1.1B

<p><em>Two weeks after Helene, 1-in-100 year Hurricane Milton exacerbates damages in Florida, America's Second Most Valuable Real Estate Market&nbsp;</em></p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="678" height="1024" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/05132301/cody-reed-vN0b_79oMyE-unsplash-678x1024.jpg" alt="" class="wp-image-2979" style="width:auto;height:450px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/05132301/cody-reed-vN0b_79oMyE-unsplash-678x1024.jpg 678w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/05132301/cody-reed-vN0b_79oMyE-unsplash-199x300.jpg 199w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/05132301/cody-reed-vN0b_79oMyE-unsplash-768x1159.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/05132301/cody-reed-vN0b_79oMyE-unsplash.jpg 795w" sizes="(max-width: 678px) 100vw, 678px" /></figure></p>
<p><em>(photo credit: Cody Reed)</em></p>
<p>Legend says that a Tocobagan blessing for sacred grounds in Tampa Bay has protected the area from hurricane devastation these last hundred years. <a href="https://www.benzinga.com/topic/hurricane-milton">Hurricane Milton</a> put this charm to the biggest test yet, ultimately landing 60 miles south. Though that averted the catastrophic loss scenario of a direct hit on West Florida's most densely populated region of&nbsp;<a href="https://apnews.com/article/hurricane-helene-florida-storm-surge-0284042dade78e04e453ad821e6e15c3#" target="_blank" rel="noreferrer noopener">3 million people</a>, storm surge and vicious winds still inflicted damage from ripping off stadium roofing to leaving nearly&nbsp;<a href="https://outage.tecoenergy.com/" target="_blank" rel="noreferrer noopener">600,000 TECO customers</a>&nbsp;without power in high 80 degree weather. This compounds misery from <a href="https://www.benzinga.com/topic/hurricane-helene">Helene's wreckage</a>, which already damaged nearly&nbsp;<a href="https://www.fox13news.com/news/hurricane-helene-where-tampa-bay-area-stand-one-week-after-storm" target="_blank" rel="noreferrer noopener">50,000 buildings and took 12 lives</a>&nbsp;locally.</p>
<h3 class="wp-block-heading"><strong>1-in-100 Year Hurricane Compounds Helene's Destruction</strong></h3>
<p>Early estimates price Milton's damage to Florida at&nbsp;<a href="https://www.bloomberg.com/news/live-blog/2024-10-10/hurricane-milton-strikes-florida?cursorId=6707D5F1B21C0000" target="_blank" rel="noreferrer noopener">$60 billion-75 billion</a>, a state with&nbsp;<a href="https://www.insurancejournal.com/magazines/mag-features/2013/06/17/295207.htm#:~:text=For%20Florida%2C%20this%20coastal%20percentage,values%20for%20the%20entire%20state" target="_blank" rel="noreferrer noopener">$3.6 trillion worth of insured property</a>&nbsp;and the nation's second most valuable residential housing market. The full scope of damages will be revealed once residents return from evacuation and file losses. Some homeowners in St. Petersburg, where Milton was a 1-in-1,000 year rainfall event, already faced total losses after Helene. More may join those ranks.&nbsp;</p>
<h3 class="wp-block-heading"><strong>Recovery Routes For Businesses And Homeowners  </strong></h3>
<p>For affected policyholders, the first line of recovery is to file claims for flood and homeowners insurance. However, many waterfront properties are uninsured because of their excessive risk exposure. Those homeowners and ones whose damages exceed insurance coverage may find relief in FEMA assistance and SBA disaster loans.&nbsp;</p>
<h3 class="wp-block-heading"><strong>Beyond Flood and Homeowners Insurance &#8211; Look to FEMA, HUD, and SBA</strong></h3>
<p>In the aftermath of Hurricane Helene, Americans felt abandoned by the perceived lack of federal resources to support survivors. While a $750 emergency credit line was the most publicized aid, the US government provides more holistic programs for disaster relief. DisasterAssistance.gov's&nbsp;<a href="https://www.disasterassistance.gov/get-assistance/find-assistance" rel="noreferrer noopener" target="_blank">application form</a>&nbsp;guides applicants to available resources from employment to housing to food assistance.&nbsp;</p>
<p>Additionally, the&nbsp;<a href="https://www.disasterassistance.gov/get-assistance/forms-of-assistance/4703#:~:text=Program%20Description,to%20rehabilitate%20your%20existing%20home." rel="noreferrer noopener" target="_blank">Department of Housing and Urban Development (HUD)</a>&nbsp;offers several programs for homeowners:</p>
<ul>
<li>Section 203(h) provides mortgage insurance to buy or rebuild a primary home.&nbsp;</li>
<li>Section 203(k) provides mortgages to buy or refinance a home.&nbsp;</li>
<li>For structural repairs, a Limited 203(k) loan can cover up to $35,000 of work.&nbsp;</li>
<li>Mobile homeowners can find relief through the Title I Manufactured Home Loan program.&nbsp;</li>
</ul>
<p>Another powerful avenue of support comes from&nbsp;<a href="https://www.sba.gov/funding-programs/disaster-assistance/physical-damage-loans" target="_blank" rel="noreferrer noopener">SBA physical damage loans</a>. Homeowners may apply for up to a $500,000 loan (after insurance coverage) capped at 4% interest ‒ significantly less than market rates ‒ to replace or repair their primary home. Renters are eligible for up to $100,000 to replace or repair personal property. Qualified businesses may be eligible for up to $2 million at 4% interest for applicants unable to obtain credit elsewhere or 8% interest for applicants with higher credit worthiness.&nbsp;</p>
<h3 class="wp-block-heading"><strong>The Last Word: File for Disaster Relief</strong></h3>
<p>The Tocobagan charm held with Milton&#8217;s eye landing south of Tampa Bay, which averted a catastrophic direct hit scenario. But strong winds and stormy waters from Helene and Milton flooded many homes, leaving piles of debris still uncleared even nearly a month after. Federal programs exist to help hurricane affected residents recover. Affected homeowners, renters, and business owners should apply as soon as possible.</p>



General

Funding for Hurricane Milton And Helene Recovery

<p>Alto Ingredients (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTO#NASDAQ">ALTO</a>) reported quarterly earnings of $0.04 per share which met the analyst consensus estimate.  The company reported quarterly sales of $251.814 million which missed the analyst consensus estimate of $267.568 million by 5.89 percent.  This is a 20.84 percent decrease over sales of $318.127 million the same period last year.</p>


Earnings

Earnings Misses

ALTO

Alto Ingredients Q3 2024 GAAP EPS $0.04, Inline, Sales $251.814M Miss $267.568M Estimate

<p>TTEC Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTEC#NASDAQ">TTEC</a>) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.14 by 21.43 percent. This is a 77.08 percent decrease over earnings of $0.48 per share from the same period last year.  The company reported quarterly sales of $529.427 million which missed the analyst consensus estimate of $539.112 million by 1.80 percent.  This is a 12.19 percent decrease over sales of $602.956 million the same period last year.</p>


TTEC

TTEC Holdings Q3 2024 Adj. EPS $0.11 Misses $0.14 Estimate, Sales $529.427M Miss $539.112M Estimate

CDRE

Cadre Holdings Sees FY24 Net Sales $560M-$571M Vs $573.297M Est.

Chord Energy Q3 2024 Adj. EPS $3.40 Misses $3.78 Estimate, Sales $1.121B Miss $1.302B Estimate

<p>Deluxe (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLX#NYSE">DLX</a>) reported quarterly earnings of $0.84 per share which beat the analyst consensus estimate of $0.74 by 13.51 percent.  The company reported quarterly sales of $528.40 million which beat the analyst consensus estimate of $525.83 million by 0.49 percent.  This is a 1.75 percent decrease over sales of $537.80 million the same period last year.</p>


Earnings Beats

Deluxe Q3 2024 Adj EPS $0.84 Beats $0.74 Estimate, Sales $528.40M Beat $525.83M Estimate

<p>Blend Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) reported quarterly sales of $45.184 million which beat the analyst consensus estimate of $41.906 million by 7.82 percent.  This is a 11.32 percent increase over sales of $40.591 million the same period last year.</p>


BLND

Blend Labs Q3 Sales $45.184M Beat $41.906M Estimate

<p>Astronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $0.08 by 525 percent.  The company reported quarterly sales of $203.700 million which beat the analyst consensus estimate of $198.610 million by 2.56 percent.  This is a 25.03 percent increase over sales of $162.922 million the same period last year.</p>


ATRO

Astronics Q3 2024 GAAP EPS $(0.34) Misses $0.08 Estimate, Sales $203.700M Beat $198.610M Estimate

<p>Host Hotels &amp; Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HST#NASDAQ">HST</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.35 by 2.86 percent. This is a 12.2 percent decrease over earnings of $0.41 per share from the same period last year.  The company reported quarterly sales of $1.32 billion which beat the analyst consensus estimate of $1.29 billion by 1.85 percent.  This is a 8.65 percent increase over sales of $1.21 billion the same period last year.</p>


Host Hotels & Resorts Q3 FFO $0.36 Beats $0.35 Estimate, Sales $1.32B Beat $1.29B Estimate

<p>"We delivered solid third quarter and year-to-date adjusted earnings resulting from infrastructure investments and disciplined cost control. As a result of this solid execution, we expect to deliver 2024 adjusted earnings within a range of $4.55 to $4.69 per share. Looking ahead, we expect our 2025 earnings per share to be in the range of $4.85 to $5.05 per share, with the midpoint representing a 7.1% increase over the midpoint of our 2024 adjusted guidance range. Further, we continue to see significant opportunity for earnings growth in the years ahead as we focus on meeting our customers' growing needs for safe, reliable, affordable and cleaner energy," said Martin J. Lyons, Jr., chairman, president and chief executive officer of Ameren Corporation. "Through consistent execution of our long-term strategy, we expect to drive sustainable earnings and dividend growth for our shareholders."</p>


Ameren Sees FY24 Adjusted Diluted EPS Guidance Range Established At $4.55-$4.69 Vs $4.62 Est.; FY25 Diluted EPS Guidance Range Established At $4.85-$5.05 Vs $4.91 Est.

<p>Veeco Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VECO#NASDAQ">VECO</a>) is looking for Q4 GAAP EPS of $0.18-0.27 vs $0.28 analyst estimate..</p>


VECO

Veeco Instruments Sees Q4 GAAP EPS $0.18-0.27 vs $0.28 Est

<p>American Coastal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.35 by 54.29 percent.  The company reported quarterly sales of $82.136 million which missed the analyst consensus estimate of $84.514 million by 2.81 percent.  This is a 47.18 percent increase over sales of $55.808 million the same period last year.</p>


ACIC

American Coastal Q3 2024 Adj. EPS $0.54 Beats $0.35 Estimate, Sales $82.136M Miss $84.514M Estimate

<p>Veeco Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VECO#NASDAQ">VECO</a>) is looking for Q4 Adj EPS of $0.35-0.45 vs $0.46 analyst estimate. seessales of $165.000 million-185.000 million vs $182.98 million estimate.</p>


Veeco Instruments Sees Q4 Adj EPS $0.35-0.45 vs $0.46 Est; Sees Sales $165.000M-185.000M vs $182.98M Est

<p>Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) reported quarterly losses of $(0.06) per share. This is a 40 percent increase over losses of $(0.10) per share from the same period last year.  The company reported quarterly sales of $101.000 thousand which missed the analyst consensus estimate of $300.000 thousand by 66.33 percent.  This is a 100.26 percent increase over sales of $50.435 thousand the same period last year.</p>


QUBT

Quantum Computing Q3 2024 GAAP EPS $(0.06) Up From $(0.10) YoY, Sales $101.000K Miss $300.000K Estimate

<p>Sterling Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) raises FY2024 GAAP EPS guidance from $5.60-5.75 to $5.85-6.00 vs $5.67 analyst estimate. Narrows FY2024 sales outlook from $2.15 billion-2.23 billion to $2.15 billion-2.17 billion vs $2.17 billion estimate.</p>


STRL

Sterling Infrastructure Raises FY2024 GAAP EPS Guidance from $5.60-5.75 to $5.85-6.00 vs $5.67 Est; Narrows FY2024 Sales Guidance from $2.15B-2.23B to $2.15B-2.17B vs $2.17B Est

<p>Tenaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TS#NYSE">TS</a>) reported quarterly earnings of $0.81 per share which beat the analyst consensus estimate of $0.66 by 22.73 percent.  The company reported quarterly sales of $2.915 billion which beat the analyst consensus estimate of $2.771 billion by 5.20 percent.  This is a 9.98 percent decrease over sales of $3.238 billion the same period last year.</p>


Tenaris Q3 2024 Adj. EPS $0.81 Beats $0.66 Estimate, Sales $2.915B Beat $2.771B Estimate

<p>Sinclair Broadcast Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBGI#NASDAQ">SBGI</a>) reported quarterly earnings of $1.43 per share which beat the analyst consensus estimate of $0.98 by 45.92 percent. This is a 293.24 percent increase over losses of $(0.74) per share from the same period last year.  The company reported quarterly sales of $917.00 million which missed the analyst consensus estimate of $923.00 million by 0.65 percent.  This is a 19.56 percent increase over sales of $767.00 million the same period last year.</p>


SBGI

Sinclair Broadcast Group Q3 EPS $1.43 Beats $0.98 Estimate, Sales $917.00M Miss $923.00M Estimate

DoubleVerify Sees Q4 2024 Revenue $194M-$200M Vs $204.7M Estimate; Sees FY24 Revenue $660M-$666M Vs $670.45M Estimate

Avalo Therapeutics (AVTX) has issued an announcement. Avalo Therapeutics, Inc. has appointed the seasoned legal professional Paul Varki as their ne...

Avalo Therapeutics Welcomes New Chief Legal Officer Paul Varki

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Avalo Therapeutics (AVTX – Research Report), with a price t...

Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX)

An update from Avalo Therapeutics (AVTX) is now available. Avalo Therapeutics has appointed Dr. Mittie Doyle as its new Chief Medical Officer, brin...

Avalo Therapeutics Welcomes New CMO with Competitive Package

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>It could be quite beneficial to invest in personalized nutrition stocks for this month in July.</p>



<p>Some applications in the personalized nutrition market are now using artificial intelligence and machine learning, or ML, to provide consumers with more <a href="https://www.futuremarketinsights.com/reports/personalized-nutrition-market">targeted</a> and therefore better advice on their diet.</p>



<p>New algorithms and AI are being designed and individual genetic, microbiome and biometric data are being used to design diets. Advancements include DNA and blood profiling of the consumer, where specific dietary suggestions can be provided based on the individual&rsquo;s biochemistry.&nbsp;</p>



<p>The global consumer is becoming more health <a href="https://www.snsinsider.com/reports/personalized-nutrition-market-3878">conscious</a> and seeking preventative measures to maintain their health and wellbeing. This shift is creating a need for products and services that are related to dietary counseling as per the consumer&rsquo;s need.</p>



<p>In order to meet these needs, companies are now spending their money on research and development to come up with new products; this includes personal care supplements, diet and even beverages made to fit certain styles.</p>



<p>These are durable trends in the market that will persist, so here are three personalized nutrition stocks for investors to consider that are riding high on them.</p>



<h2>23andMe (ME)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/01/23andme-300x169.jpg" alt="A close-up shot of the saliva collection kit from 23andMe."><div>Source: nevodka / Shutterstock.com</div></div><p><strong>23andMe</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/me-stock-quote/"><strong>ME</strong></a>) has a huge database of customers&rsquo; genetic information. It is primarily a therapeutics company, which makes it an attractive player in personalized nutrition stocks.<br><br>Despite the fact that the company&rsquo;s consumer genetics kit business has experienced some <a href="https://investors.23andme.com/news-releases/news-release-details/23andme-reports-fourth-quarter-and-full-year-fiscal-2024">declines</a>, the main value of 23andMe can be found in its 14 million customers who can help to develop transformational drugs.</p>



<p>23andMe has an internal pipeline of several promising therapeutics: an antibody cancer drug and a NK cell activator that is already in the clinical trials.&nbsp;</p>



<p>It has also expanded the rest of its consumer genetics business, which includes a recently launched set of new premium features that offer users personal health information. The company&rsquo;s use of genetic information and pharmaceutical research gives it an edge in the fast-emerging field of personalized medicine and the potential for significant future revenues.</p>



<p>ME stock then is one of those personalized nutrition stocks to consider, as it combines a deep understanding of genetics and personalized medicine to offer nutritional insights.</p>



<h2>Avalo Therapeutics (AVTX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/medicines-therapeutics-300x169.png" alt="Animated image of different medications"><div>Source: Olga Kononok/Shutterstock</div></div><p><strong>Avalo Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/avtx-stock-quote/"><strong>AVTX</strong></a>) is one of the best personalized nutrition stocks to consider now. Avalo is a clinical-stage biotech company, whose primary focus is to develop new therapies to manage immune dysregulation, with the goal of using the body&rsquo;s inflammatory pathways to treat various diseases.&nbsp;</p>



<p>The core of Avalo&rsquo;s pipeline consists of <a href="https://ir.avalotx.com/press-releases/detail/186/avalo-reports-first-quarter-2024-financial-results-and">AVTX-009</a>, a monoclonal antibody that the company claims to have a great prospect in treating hidradenitis suppurativa, or HS, a recurrent and usually painful inflammatory skin disease.&nbsp;</p>



<p>Avalo has high hopes for AVTX-009 based on its plans to progress it to a Phase II trial, which is expected to produce top line results in 2026.</p>



<p>Given that there is a large population of patients with unmet needs and a multi-billion dollar market opportunity in HS, approval of AVTX-009 may be a breakthrough in the treatment of this condition.&nbsp;</p>



<p>&nbsp;Of importance, Avalo has recently acquired AlmataBio and received $185 million financing. This has strengthened the company&rsquo;s capability and the company&rsquo;s cash runway into 2027. This, then, positions the company as one of those personalized nutrition stocks to buy.</p>



<h2>Veracyte (VCYT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/healthy-food-300x169.jpg" alt="BSFC Stock. Healthy food including salmon, almonds, garlic, broccoli, avocado, and lettuce"><div>Source: Shutterstock.com</div></div><p>As one of the best personalized nutrition stocks to buy now,<strong> Veracyte</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcyt-stock-quote/"><strong>VCYT</strong></a>) is a company to watch. Being a global diagnostics company that is committed to revolutionizing cancer treatment, Veracyte&rsquo;s vision on the use of personalized medicine and nutrition is appropriate, given the increasing adoption of evidence-based, patient-specific approaches to healthcare.&nbsp;</p>



<p>The core of Veracyte&rsquo;s strategy is the <a href="https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-first-quarter-2024-financial-results">Veracyte Diagnostics Platform</a> &mdash; a combination of genomic and clinical data, bioinformatics and AI &mdash; that allows the company to create effective cancer tests. This enables Veracyte to develop therapies new and increase its range of personalized diagnostic tests leveraging the liquid biopsy.</p>



<p>VCYT&rsquo;s intersection with personalized nutrition is not as direct as some of the other companies on this list, but there is a strong enough synergy here with oncology to suggest it&rsquo;s one of those stocks to watch.</p>



<p>VCYT has also caught the attention of analysts, with positive earnings per share <a href="https://stockanalysis.com/stocks/vcyt/forecast/">forecasts</a> on the horizon and a growing top line.</p>



<p><em>On the date of publication, Matthew Farley did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed are those of the writer, subject to the<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"> InvestorPlace.com Publishing Guidelines</a>.</em></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>Matthew started writing coverage of the financial markets during the crypto boom of 2017 and was also a team member of several fintech startups. He then started writing about Australian and U.S. equities for various publications. His work has appeared in MarketBeat, FXStreet, Cryptoslate, Seeking Alpha, and the New Scientist magazine, among others.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
<p>The post <a href="https://investorplace.com/2024/07/the-3-best-personalized-nutrition-stocks-to-buy-now/">The 3 Best Personalized Nutrition Stocks to Buy Now</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

The 3 Best Personalized Nutrition Stocks to Buy Now

Avalo Therapeutics GAAP EPS of -$14.07

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Avalo Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/avtx-stock-quote/"><strong>AVTX</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Avalo Therapeutics reported earnings per share of -$14.07. This was below the analyst estimate for EPS of -$6.70.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/avtx-stock-earnings-avalo-therapeutics-for-q2-of-2024/">AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024

An update from Avalo Therapeutics (AVTX) is now available. At the 2024 Annual Meeting of the Company, a significant 58% of shareholders participate...

Avalo Therapeutics Shareholders Back Board and Strategies

Oppenheimer Sticks to Their Buy Rating for Avalo Therapeutics (AVTX)

Avalo Therapeutics (AVTX) has received a new Hold rating, initiated by H.C. Wainwright analyst, Edward White. Edward White's rating is based on a c...

Cautious Outlook on Avalo Therapeutics Amid Early-Stage Development and Financial Risks

H.C. Wainwright analyst Edward White initiated coverage of Avalo Therapeutics (AVTX) with a Neutral rating and no price target The firm says the co...

Comments

Avalo Therapeutics

Notizie

Ultime notizie per Avalo Therapeutics (NASDAQ:AVTX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO